216
Participants
Start Date
January 26, 2017
Primary Completion Date
November 19, 2019
Study Completion Date
February 26, 2020
SOF/VEL
SOF/VEL fixed-dose combination (FDC) 400/100 mg tablets or SOF/VEL FDC 200/50 mg tablets (based on swallowability assessment)
SOF/VEL
SOF/VEL FDC 200/50 mg oral granules
Cliniques Universitaires Saint Luc, Brussels
Mount Sinai Medical Center, New York
The Children's Hospital of Philadelphia, Philadelphia
Children's National Medical Center, Washington D.C.
Johns Hopkins University (JHU) - The Johns Hopkins Hospital (JHH), Baltimore
Emory Children's Center, Atlanta
University of Florida Shands Medical, Gainesville
Florida Gastroenterology Care for Children, Orlando
Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville
Azienda Ospedaliero-Universitaria di Bologna - Policlinico S. Orsola - Malpighi, Bologna
Kosair Charities Pediatric Clinical Research Unit, Louisville
Nationwide Children's Hospital- The Ohio State University (OSU), Columbus
Cincinnati Children's Hospital Medical Center, Cincinnati
Riley Hospital for Children, Indianapolis
Azienda Ospedaliera Universitaria Meyer, Florence
Children's Mercy Hospital, Kansas City
Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo
Cook Children's Medical Center, Fort Worth
Baylor College of Medicine, Houston
Children's Hospital of Colorado, Aurora
Children's Hospital Los Angeles, Los Angeles
University of California, San Francisco, San Francisco
Seattle Children's Hospital, Seattle
Boston Children's Hospital, Boston
Children's Hospital & Medical Center, Omaha
The Leeds Teaching Hospitals NHS Trust, Leeds
King's College Hospital NHS Trust, London
Lead Sponsor
Gilead Sciences
INDUSTRY